-
1.发明授权公开(公告)号：US09372198B2
公开(公告)日：2016-06-21
申请号：US13162344
申请日：2011-06-16
Applicant: Igor Gonda
Inventor： Igor Gonda
CPC classification number: G01N33/94 , A61B5/082 , A61B5/14 , A61B5/150022 , A61B5/411 , A61B5/4211 , G01N21/6486 , G01N33/6893 , G01N2800/06
Abstract: The invention provides a method of diagnosing entry of gastrointestinal contents into the respiratory tract of a patient suffering from reflux disease. The method comprises orally administering to a subject formulation comprising a detectable label that is not absorbed from the gastrointestinal tract but can be absorbed from the respiratory tract. The extent of the gastrointestinal contents entering the respiratory tract can be estimated by measuring the level of the detectable label in a body fluid, e.g., blood or urine.
Abstract translation: 本发明提供了一种诊断胃肠内容物进入患有反流疾病的患者的呼吸道的方法。 该方法包括口服给予包含不能从胃肠道吸收但可从呼吸道吸收的可检测标记物的主体制剂。 进入呼吸道的胃肠内容物的程度可以通过测量体液例如血液或尿液中可检测标记的水平来估计。
-
公开(公告)号：US08689803B2
公开(公告)日：2014-04-08
申请号：US13562786
申请日：2012-07-31
Applicant: Igor Gonda
Inventor： Igor Gonda
CPC classification number: A61K31/4439 , A24F47/002 , A61K9/0078 , A61M15/008 , A61M15/009 , A61M15/06 , A61M16/10 , A61M2209/06
Abstract: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.
Abstract translation: 本发明一般涉及用于治疗对尼古丁治疗反应的病症的系统和方法。 更具体地，本发明涉及含有尼古丁的制剂的肺部给药以实现戒烟。
-
公开(公告)号：US08435944B2
公开(公告)日：2013-05-07
申请号：US11445463
申请日：2006-06-02
Applicant: Tony Dipietro , Andrew Humberstone , Igor Gonda , Adam Watkinson , Kerrie Setiawan , Nina Wilkins
Inventor： Tony Dipietro , Andrew Humberstone , Igor Gonda , Adam Watkinson , Kerrie Setiawan , Nina Wilkins
CPC classification number: A61K31/568 , A61K8/37 , A61K9/0014 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/32 , A61Q17/04
Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
-
公开(公告)号：US08381739B2
公开(公告)日：2013-02-26
申请号：US12208176
申请日：2008-09-10
Applicant: Igor Gonda
Inventor： Igor Gonda
IPC: A24F47/00
CPC classification number: A61K31/4439 , A24F47/002 , A61K9/0078 , A61M15/008 , A61M15/009 , A61M15/06 , A61M16/10 , A61M2209/06
Abstract: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.
Abstract translation: 本发明一般涉及用于治疗对尼古丁治疗反应的病症的系统和方法。 更具体地，本发明涉及含有尼古丁的制剂的肺部给药以实现戒烟。
-
5.发明申请Method of Use of Monomeric Insulin as a Means for Improving the Reproducibility of Inhaled Insulin 审中-公开使用单体胰岛素作为改善吸入胰岛素再现性的手段的方法公开(公告)号：US20080102129A1
公开(公告)日：2008-05-01
申请号：US11924483
申请日：2007-10-25
Applicant: Igor Gonda , Reid Rubsamen , Stephen Farr
Inventor： Igor Gonda , Reid Rubsamen , Stephen Farr
CPC classification number: A61K9/007 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61K9/0073 , A61K9/0075 , A61K38/28 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0045 , A61M15/0051 , A61M15/0065 , A61M15/0066 , A61M15/008 , A61M15/0085 , A61M15/009 , A61M16/142 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206
Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
Abstract translation: 可以通过递送雾化的单体胰岛素制剂来减少或消除通过注射递送胰岛素的需要。 相对于常规胰岛素，给药的重复性更特别是血液浓度对时间曲线的重复性得到改善。 血液浓度与时间分布基本上不受患者在分娩时呼吸机动的特定方面的影响。 此外，通过使用单体胰岛素来增加血糖降低的速度。 胰岛素的颗粒，特别是递送到肺组织表面的单体胰岛素将被吸收到循环系统中。 单体胰岛素可以是干粉，但是优选地是从手持式独立装置输送到患者的液体制剂，其自动释放雾化的制剂爆发。 该装置包括传感器，其优选是电子的，其测量吸气流量和体积，该测量可用于控制药物释放点。
-
Patent Agency Ranking
6.发明申请METHOD OF USE OF MONOMERIC INSULIN AS A MEANS FOR IMPROVING THE REPRODUCIBILITY OF INHALED INSULIN 审中-公开使用单一胰岛素作为改善吸入胰岛素可重复性的手段的方法公开(公告)号：US20080099010A1
公开(公告)日：2008-05-01
申请号：US11924503
申请日：2007-10-25
Applicant: Igor Gonda , Reid Rubsamen , Stephen Farr
Inventor： Igor Gonda , Reid Rubsamen , Stephen Farr
IPC: A61M11/00
CPC classification number: A61K9/007 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61K9/0073 , A61K9/0075 , A61K38/28 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0045 , A61M15/0051 , A61M15/0065 , A61M15/0066 , A61M15/008 , A61M15/0085 , A61M15/009 , A61M16/142 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206
Abstract: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
Abstract translation: 可以通过递送雾化的单体胰岛素制剂来减少或消除通过注射递送胰岛素的需要。 相对于常规胰岛素，给药的重复性更特别是血液浓度对时间曲线的重复性得到改善。 血液浓度与时间分布基本上不受患者在分娩时呼吸机动的特定方面的影响。 此外，通过使用单体胰岛素来增加血糖降低的速度。 胰岛素的颗粒，特别是递送到肺组织表面的单体胰岛素将被吸收到循环系统中。 单体胰岛素可以是干粉，但是优选地是从手持式独立装置输送到患者的液体制剂，其自动释放雾化的制剂爆发。 该装置包括传感器，其优选是电子的，其测量吸气流量和体积，该测量可用于控制药物释放点。
-
7.发明授权Method of fabricating porous membrane with unique pore structure for aerosolized delivery of drugs 有权制造具有独特孔结构的多孔膜用于药物雾化递送的方法公开(公告)号：US06551542B1
公开(公告)日：2003-04-22
申请号：US09710612
申请日：2000-11-08
Applicant: Rajesh S. Patel , Sudarsan Srinivasan , Russell M. Pon , Jeffrey A. Schuster , Igor Gonda
Inventor： Rajesh S. Patel , Sudarsan Srinivasan , Russell M. Pon , Jeffrey A. Schuster , Igor Gonda
IPC: B23K2600
CPC classification number: B23K26/382 , B23K26/066 , B23K26/40 , B23K2103/42 , B23K2103/50
Abstract: A method for producing a nozzle useful in generating a fine aerosol for delivery of therapeutic or diagnostic agents is provided. The method comprises focusing a laser source onto a thin, preferably flexible material so as to form pores substantially through the material. The pores are formed to have an unflexed exit aperture diameter in the range of about 0.5 to about 25 microns, depending on the size of the aerosol particles desired for a particular application. The nozzle may have a variety of shapes and be distributed in a variety of patterns. An elevated area can be formed around the exit aperture of the nozzle in order to prevent intrusion of liquid into the nozzle.
Abstract translation: 提供了一种用于生成用于产生用于递送治疗剂或诊断剂的细小气溶胶的喷嘴的方法。 该方法包括将激光源聚焦到薄的，优选柔性的材料上，以形成基本上通过该材料的孔。 根据特定应用所需的气溶胶颗粒的尺寸，孔被形成为具有约0.5至约25微米范围内的非折射出口孔直径。 喷嘴可以具有各种形状并且以各种图案分布。 可以在喷嘴的出口孔周围形成升高的区域，以防止液体进入喷嘴。
-
8.发明授权Minimizing thermally induced aggregation of DNase in solution with calcium 失效最小化DNA诱导的DNA溶解在钙溶液中的聚集公开(公告)号：US06383788B1
公开(公告)日：2002-05-07
申请号：US08696955
申请日：1996-12-03
Applicant: Hak-Kim Chan , Igor Gonda , Steven J. Shire , Suzanne Sin-Mui Lo Weck
Inventor： Hak-Kim Chan , Igor Gonda , Steven J. Shire , Suzanne Sin-Mui Lo Weck
IPC: C12N996
CPC classification number: C12N9/22 , A61K36/534 , A61K36/9068 , A61K38/00 , A61K38/018 , A61K45/06 , C12N9/96 , C12Y301/21001 , A61K2300/00
Abstract: The present invention relates to the use of calcium ion and/or sugars to minimize thermal aggregation of DNase and to the use of calcium ion to stabilize liquid solutions of DNase, the solutions having a pH of less than neutral. DNase is the active pharmaceutical principle and the solutions may contain other pharmaceutically acceptable excipients making them suitable for pharmaceutical administration. In the first instance, calcium ion/sugar minimizes the effects of thermal aggregation in the solution. In the second aspect, calcium ion stabilizes the lower pH solutions from protein precipitation.
Abstract translation: 本发明涉及钙离子和/或糖的使用以使DNA酶的热聚集最小化，并且使用钙离子来稳定DNase的液体溶液，该溶液具有小于中性的pH。 DNase是活性药物原理，并且该溶液可以含有其它药学上可接受的赋形剂，使得它们适合于药物施用。 首先，钙离子/糖最小化溶液中热聚集的影响。 在第二方面，钙离子使蛋白质沉淀中的较低pH值溶液稳定。
-
公开(公告)号：US5884620A
公开(公告)日：1999-03-23
申请号：US846243
申请日：1997-04-25
Applicant: Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
Inventor： Igor Gonda , Reid M. Rubsamen , Stephen J. Farr
CPC classification number: A61K9/007 , A61K38/28 , A61K9/0073 , A61M11/001 , A61M15/00 , A61M15/0031 , A61M15/0043 , A61M15/0045 , A61M15/0051 , A61M15/0066 , A61M15/008 , A61M16/142 , A61J7/0418 , A61J7/0427 , A61J7/0445 , A61M15/0085 , A61M15/009 , A61M2016/0021 , A61M2016/0036 , A61M2202/062 , A61M2202/064 , A61M2205/50 , A61M2205/8206 , Y10S514/866
Abstract: Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied.
-
公开(公告)号：US5457044A
公开(公告)日：1995-10-10
申请号：US145922
申请日：1993-10-29
Applicant: David C. Cipolla , Igor Gonda
Inventor： David C. Cipolla , Igor Gonda
CPC classification number: C12N9/22 , B01D39/201 , C07K1/34
Abstract: A method for collecting an aerosolized therapeutic polypeptide of interest, such as recombinant human deoxyribonuclease I (rhDNase), is provided which enables a determination as to the effect aerosolization has on the activity and integrity of the polypeptide. An aerosol of the polypeptide is generated using a nebulizer, for example, and the polypeptide is collected in an inert filter, such as a sintered glass filter. To increase the amount of polypeptide collected, the aerosol is preferably mixed with pre-humidified dilution air at a temperature between about 40.degree. and 55.degree. C. The collected polypeptide is subjected to biochemical activity and integrity analysis compared to the activity and integrity of the control polypeptide which has not been aerosolized.
Abstract translation: 提供了一种用于收集目的地雾化的治疗性多肽的方法，例如重组人脱氧核糖核酸酶I（rhDNase），其使得能够确定雾化对多肽的活性和完整性的影响。 例如，使用喷雾器产生多肽的气溶胶，并将多肽收集在惰性过滤器如烧结玻璃过滤器中。 为了增加收集的多肽的量，气雾剂优选在约40℃至55℃的温度下与预加湿的稀释空气混合。收集的多肽与生物化学活性和完整性分析相比，其活性和完整性 对照多肽尚未雾化。
-
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.044 seconds)
